Enveric Biosciences (ENVB) Return on Capital Employed (2011 - 2026)
Enveric Biosciences (ENVB) posted Return on Capital Employed of 169.56% for Q1 2026, up 26.36% sequentially from 230.26% in Q4 2025, and up 15172.0% YoY from N/an in Q1 2025.
Enveric Biosciences (ENVB) Return on Capital Employed (2011 - 2026) Analysis & Trends
Enveric Biosciences has reported Return on Capital Employed for 16 years, with the latest figure at 169.56% in Q1 2026.
- Quarterly Return on Capital Employed rose 15172.0% year-over-year to 169.56% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 169.56% (up 15172.0% YoY) and the FY2025 annual result came in at 276.72%, up 16082.0% from the prior year.
- Return on Capital Employed grew to 169.56% in Q1 2026 per ENVB's latest filing, from 230.26% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 129.27% in Q4 2022 and troughed at 653.72% in Q3 2023.
- A 5-year average of 295.8% and a median of 243.91% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 40981 bps in 2023, then surged 46072 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 129.27% in 2022, then slumped by 308 bps to 527.87% in 2023, then gained by 25 bps to 393.69% in 2024, then surged by 42 bps to 230.26% in 2025, then increased by 26 bps to 169.56% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 169.56%, 230.26%, and 319.88% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | -137.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -169.56% |
| Dec 31, 2025 | -230.26% |
| Sep 30, 2025 | -319.88% |
| Jun 30, 2025 | -336.43% |
| Mar 31, 2025 | -321.28% |
| Dec 31, 2024 | -393.69% |
| Sep 30, 2024 | -193.00% |
| Jun 30, 2024 | -150.00% |
| Mar 31, 2024 | -334.34% |
| Dec 31, 2023 | -527.87% |
| Sep 30, 2023 | -653.72% |
| Jun 30, 2023 | -361.08% |
| Mar 31, 2023 | -207.17% |
| Dec 31, 2022 | -129.27% |
| Sep 30, 2022 | -243.91% |
| Jun 30, 2022 | -228.15% |
| Mar 31, 2022 | -229.04% |
| Dec 31, 2021 | -142.03% |
| Sep 30, 2021 | -38.53% |
| Jun 30, 2021 | -59.99% |